Daily Intelligence Brief
Weekly Docket: Talc, Suboxone, and Depo-Provera Drive 734 Federal Filings
LexGenius tracked 734 new federal filings across 582 dockets last week, with volume concentrated in mass-tort pharmaceutical and consumer-product MDLs. The Johnson & Johnson Talcum Powder Products Liability Litigation (MDL 2738) led with 209 filings paced by Duncan Stubbs / OnderLaw LLC (149) and Napoli Shkolnik (37); the Suboxone Film Products Liability Litigation (MDL 3092) added 152 plaintiffs across two mass-joinder dockets filed by Keller Postman LLC (100 plaintiffs) and Peiffer Wolf (52); the Depo-Provera Products Liability Litigation (MDL 3140) logged 66 new suits paced by The Miller Firm LLC and Ben Martin Law Group (7 each); and the Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (MDL 3060) added 53 cases distributed across a broad plaintiff bar.Trial Calendar Heats Up: Ozempic Motion Deadlines This Week, Uber Bellwether Verdict, Depo-Provera Hearings on Deck
The Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation (MDL 3094) hits two pivotal filing deadlines this week before Judge Karen S. Marston (E.D. Pa.): Daubert motions to exclude general-causation experts are due April 28, 2026 and summary-judgment motions are due April 30, 2026 — the most consequential paper drop of the quarter for Novo Nordisk and Eli Lilly, after Marston previously required plaintiffs to produce objective gastric-emptying studies. On April 20, a federal jury in the Uber Technologies Passenger Sexual Assault Litigation (MDL 3084) found Uber liable in the Mensing bellwether out of W.D.N.C. and awarded roughly $5,000 — damages were capped at a single 24-hour window without accounting for lasting emotional impact, a sharp contrast to the prior Dean verdict of $8.5 million; the next two consecutive bellwethers begin September 14, 2026 in N.D. Cal. before Judge Charles R. Breyer. The Depo-Provera Products Liability Litigation (MDL 3140) has general-causation Daubert hearings rescheduled to June 24–26, 2026 before Judge M. Casey Rodgers (N.D. Fla.), with the first bellwether (Toney v. Pfizer) set for December 7, 2026 and a pilot pool that also includes Blonski, Schmidt, Wilson, and Valera-Arceo.JPML Scale Snapshot and Bellwether Pipelines Across the Largest Pending MDLs
Against the JPML's most recent active-dockets baseline, last week's volume sits inside several of the largest pending MDLs. The Talcum Powder Litigation carries 67,376 pending dockets before Judge Michael A. Shipp (D.N.J.), where an April 8, 2026 status order required the parties to submit a joint update on pretrial motions and trial readiness with Carter Judkins selected as the next bellwether case. The Suboxone MDL holds 1,836 pending dockets before Judge J. Philip Calabrese (N.D. Ohio); the new CMO directs 20 of 100 cases into core discovery by June 10, 2026, with depositions running through January 15, 2027, dispositive motions due March 12, 2027, and the first trial set for March 2028. The Hair Relaxer Litigation sits at 11,371 pending dockets before Judge Mary M. Rowland (N.D. Ill.), who on April 8, 2026 selected a 10-case bellwether pool to advance into core discovery. GLP-1 RAs (MDL 3094) stands at 3,546 pending dockets, Depo-Provera (MDL 3140) at 3,490, and the Social Media Adolescent Addiction Litigation (MDL 3047) at 2,465 pending dockets before Judge Yvonne Gonzalez Rogers (N.D. Cal.) — where the second pretrial conference and MSJ motions hearing was held April 14–15, 2026 and the parallel state bellwether (K.G.M. v. Meta/YouTube) returned a $6 million plaintiff verdict in late March.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
